| European Case Law Identifier: | ECLI:EP:BA:2017:T072511.20170313 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 13 March 2017 | ||||||||
| Case number: | T 0725/11 | ||||||||
| Application number: | 04701819.7 | ||||||||
| IPC class: | A61K 31/675 A61K 31/513 A61P 31/18 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | ||||||||
| Applicant name: | GILEAD SCIENCES, INC. | ||||||||
| Opponent name: | Teva Pharmaceutical Industries LTD. Generics (UK) Limited |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | - | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t110725eu1.html
Date retrieved: 17 May 2021